Characterization of the major DNA adducts in the liver of rats chronically exposed to tamoxifen for 18 months

Chemico-Biological Interactions

Volumn 126, Issue 1, 2000, Pages 33-43

  Firoz Firozi, Pervez ^a   Vulimiri, Suryanarayana V ^a   Rajaniemi, Heli ^b   Hemminki, Kari ^b   Dragan, Yvonne ^c   Pitot, Henry C ^c   Digiovanni, John ^a   Zhu, Yong Hong ^a   Li, Donghui ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

N desmethyl TAM N2 deoxyguanine; TAM N2 deoxyguanine; Chronic exposure; DNA adducts; Rat liver; Tamoxifen

Indexed keywords

TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHROMATOGRAPHY; DNA ADDUCT; DNA MODIFICATION; DRUG ACCUMULATION; DRUG DNA BINDING; FEMALE; LIVER CARCINOGENESIS; LONG TERM EXPOSURE; NONHUMAN; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOGENS; DNA ADDUCTS; FEMALE; LIVER; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; TAMOXIFEN;

EID: 0034647097     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(00)00151-4     Document Type: Article

References (26)

1. Powles T.J. Status of antiestrogen breast cancer prevention trials. Oncology. 123(Suppl. 5):1998;28-31.
2. Fisher B., Costantino J.P., Redmond C.K. et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86:1994;527-537.
3. Magriples U., Naftolin F., Schwartz P. et al. High grade endometrial carcinoma in tamoxifen treated breast cancer patients. J. Clin. Oncol. 11:1993;448-452.
4. IARC Monographs on the Evaluation of Carcinogenic Risks to Human, Vol 66, Some Pharmaceutical Drugs, Lyon, 1996, pp. 201-225.
5. Tannebaum S.R. Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity. Semin. Oncol. 24:1997;81-86.
6. Phillips D.H., Potter G.A., Horton M.N. et al. Reduced genotoxicity of [D5-ethyl] tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis. 15:1994;1487-1492.
7. Phillips D.H., Carmichael P.L., Hewer A. et al. Alpha-hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res. 54:1994;5518-5522.
8. Phillips D.H., Carmichael P.L., Hewer A. et al. Activation of tamoxifen and its metabolite α-hydroxy tamoxifen to DNA-binding products: comparison between human, rat and mouse hepatocytes. Carcinogenesis. 17:1996;89-94.
9. Rajaniemi H., Koskinen M., Mantyla E. et al. DNA binding of tamoxifen and its analogues: identification of the tamoxifen-DNA adducts in rat liver. Toxicol. Letts. 102-103:1998;453-457.
10. Phillips D.H., Hewer A., Horton M.N. et al. N-demethylation accompanies α-hydroxylation in the metabolic activation of tamoxifen in rat liver cells. Carcinogenesis. 20:1999;2003-2009.
11. Davis A.M., Martin E.A., Jones R.M. et al. Peroxidase activation of tamoxifen and toremifene resulting DNA damage and covalently bound protein adducts. Carcinogenesis. 16:1995;539-545.
12. Marques M.M., Beland F.A. Identification of tamoxifen-DNA adducts formed by 4-hydroxy quinone methide. Carcinogenesis. 18:1997;1949-1954.
13. Osborne M.R., Hewer A., Hardcastle I.R. et al. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56:1996;66-71.
14. Beland F.A., McDaniel L.P., Marques M.M. Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. Carcinogenesis. 20:1999;471-477.
15. Osborne M.R., Davis W., Hewer A.J. et al. 4-Hydroxytamoxifen gives DNA adducts by chemical activation, but not in rat liver cells. Chem. Res. Toxicol. 12:1999;151-158.
16. 32P-postalbelled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC method. Carcinogenesis. 19:1998;1061-1069.
17. Shibutani S., Dasaradhi L., Terashima I. et al. α-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res. 58:1998;647-653.
18. Dasaradhi L., Shibutani S. Identification of tamoxifen-DNA adducts formed by ∝-sulfate tamoxifen and α-acetoxytamoxifen. Chem. Res. Toxicol. 10:1997;189-196.
19. Rajaniemi H., Rasanen I., Koivisto P. et al. Identification of the major tamoxifen-DNA adducts in rat liver by mass spectroscopy. Carcinogenesis. 20:1999;305-309.
20. Brown K., Heydon R.T., Jukes R. et al. Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen. Carcinogenesis. 20:1999;2011-2016.
21. Li D., Dragan Y., Jordan V.C. et al. Effect of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney and uterus. Cancer Res. 57:1997;1438-1441.
22. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumor formation. Carcinogenesis. 16:1995;1299-1304.
23. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis. 7:1986;1543-1551.
24. 32P-postlabeling assay based on the specific enzymatic conversion of bulky DNA lesions to radiolabeled dinucleotides and nucleoside 5′-monophosphates. Carcinogenesis. 10:1989;1231-1239.
25. Phillips D.H., Hewer A., White I.N.H. et al. Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major adduct formed in the livers of tamoxifen-treated rats. Carcinogenesis. 15:1994;793-795.
26. 2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res. 59:1999;2091-2095.